CY1114928T1 - Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης - Google Patents
Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινηςInfo
- Publication number
- CY1114928T1 CY1114928T1 CY20131100881T CY131100881T CY1114928T1 CY 1114928 T1 CY1114928 T1 CY 1114928T1 CY 20131100881 T CY20131100881 T CY 20131100881T CY 131100881 T CY131100881 T CY 131100881T CY 1114928 T1 CY1114928 T1 CY 1114928T1
- Authority
- CY
- Cyprus
- Prior art keywords
- immunization
- adenosine receptors
- myocardial blood
- myocardial
- adenosine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
Μέθοδος αιμάτωσης μυοκαρδίου που επιτυγχάνεται χορηγώντας έναν ή περισσότερους αγωνιστές υποδοχείς αδενοσίνης Α2Α σε άνθρωπο που υποβάλλεται σε απεικόνιση μυοκαρδίου όπως επίσης και φαρμακευτικές συνθέσεις που περιλαμβάνουν τουλάχιστον έναν αγωνιστή υποδοχέα Α2Α, τουλάχιστον ένα υγρό όχημα, και τουλάχιστον έναν συνδιαλύτη.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2004/002304 WO2005082379A1 (en) | 2004-01-27 | 2004-01-27 | Myocardial perfusion imaging using adenosine receptor agonists |
EP10011221.8A EP2366396B1 (en) | 2004-01-27 | 2004-01-27 | Myocardial perfusion imaging using adenosine receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114928T1 true CY1114928T1 (el) | 2016-12-14 |
Family
ID=34912870
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100881T CY1114928T1 (el) | 2004-01-27 | 2013-10-09 | Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης |
CY20131100913T CY1115926T1 (el) | 2004-01-27 | 2013-10-16 | Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100913T CY1115926T1 (el) | 2004-01-27 | 2013-10-16 | Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης |
Country Status (16)
Country | Link |
---|---|
EP (2) | EP2366396B1 (el) |
JP (1) | JP4818127B2 (el) |
KR (1) | KR101143826B1 (el) |
CN (1) | CN1905887A (el) |
AU (1) | AU2004316372B2 (el) |
CA (2) | CA2691611A1 (el) |
CY (2) | CY1114928T1 (el) |
DK (2) | DK2366396T3 (el) |
ES (2) | ES2428843T3 (el) |
HK (1) | HK1162139A1 (el) |
IL (1) | IL177119A (el) |
NO (1) | NO337132B1 (el) |
NZ (1) | NZ548794A (el) |
PT (2) | PT2366396E (el) |
SI (2) | SI1708721T1 (el) |
WO (1) | WO2005082379A1 (el) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
US6214807B1 (en) | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US20020012946A1 (en) | 2000-02-23 | 2002-01-31 | Luiz Belardinelli | Method of identifying partial agonists of the A2A receptor |
NZ537975A (en) | 2002-07-29 | 2007-08-31 | Cv Therapeutics Inc | Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
EP1802317A2 (en) * | 2004-10-20 | 2007-07-04 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
US7732595B2 (en) | 2006-02-03 | 2010-06-08 | Gilead Palo Alto, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
US20080267861A1 (en) * | 2007-01-03 | 2008-10-30 | Cv Therapeutics, Inc. | Myocardial Perfusion Imaging |
WO2009108829A2 (en) * | 2008-02-29 | 2009-09-03 | King Pharmaceuticals Research And Development, Inc. | Crystal forms of 2-{2-[(cyclohexyl)methylene]hydrazino}adenosine |
BRPI0918962A2 (pt) * | 2008-09-29 | 2015-12-01 | Gilead Sciences Inc | combinações de um agente de controle de taxa e um antagonista do receptor a-2-alfa para utilização em métodos tomografia computadorizada de multidetectores |
JP2011098990A (ja) * | 2011-02-21 | 2011-05-19 | Gilead Palo Alto Inc | アデノシン受容体作動薬を使用する心筋灌流イメージング方法 |
RU2502461C1 (ru) * | 2012-06-04 | 2013-12-27 | Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "РКНПК" Минздравсоцразвития России) | Способ диагностики ишемии миокарда у больных кардиальным синдромом х |
US20190240247A1 (en) * | 2016-09-01 | 2019-08-08 | Leiutis Pharmaceuticals Pvt. Ltd. | Pharmaceutical formulations of regadenoson |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6026317A (en) * | 1998-02-06 | 2000-02-15 | Baylor College Of Medicine | Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists |
US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US20020012946A1 (en) * | 2000-02-23 | 2002-01-31 | Luiz Belardinelli | Method of identifying partial agonists of the A2A receptor |
NZ537975A (en) * | 2002-07-29 | 2007-08-31 | Cv Therapeutics Inc | Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist |
-
2004
- 2004-01-27 CN CNA2004800410138A patent/CN1905887A/zh active Pending
- 2004-01-27 JP JP2006551022A patent/JP4818127B2/ja not_active Expired - Lifetime
- 2004-01-27 KR KR1020067015150A patent/KR101143826B1/ko active IP Right Grant
- 2004-01-27 EP EP10011221.8A patent/EP2366396B1/en not_active Expired - Lifetime
- 2004-01-27 ES ES10011221T patent/ES2428843T3/es not_active Expired - Lifetime
- 2004-01-27 EP EP04705715.3A patent/EP1708721B1/en not_active Expired - Lifetime
- 2004-01-27 ES ES04705715T patent/ES2426913T3/es not_active Expired - Lifetime
- 2004-01-27 AU AU2004316372A patent/AU2004316372B2/en not_active Expired
- 2004-01-27 WO PCT/US2004/002304 patent/WO2005082379A1/en not_active Application Discontinuation
- 2004-01-27 PT PT100112218T patent/PT2366396E/pt unknown
- 2004-01-27 DK DK10011221.8T patent/DK2366396T3/da active
- 2004-01-27 PT PT47057153T patent/PT1708721E/pt unknown
- 2004-01-27 SI SI200432077T patent/SI1708721T1/sl unknown
- 2004-01-27 DK DK04705715.3T patent/DK1708721T3/da active
- 2004-01-27 CA CA002691611A patent/CA2691611A1/en not_active Abandoned
- 2004-01-27 CA CA2554169A patent/CA2554169C/en not_active Expired - Lifetime
- 2004-01-27 NZ NZ548794A patent/NZ548794A/xx not_active IP Right Cessation
- 2004-01-27 SI SI200432079T patent/SI2366396T1/sl unknown
-
2006
- 2006-07-27 IL IL177119A patent/IL177119A/en active IP Right Grant
- 2006-08-10 NO NO20063629A patent/NO337132B1/no not_active IP Right Cessation
-
2012
- 2012-03-13 HK HK12102535.4A patent/HK1162139A1/xx not_active IP Right Cessation
-
2013
- 2013-10-09 CY CY20131100881T patent/CY1114928T1/el unknown
- 2013-10-16 CY CY20131100913T patent/CY1115926T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2004316372B2 (en) | 2011-05-12 |
ES2428843T3 (es) | 2013-11-11 |
SI2366396T1 (sl) | 2013-10-30 |
AU2004316372A1 (en) | 2005-09-09 |
NO337132B1 (no) | 2016-01-25 |
EP1708721B1 (en) | 2013-08-07 |
NO20063629L (no) | 2006-10-26 |
PT2366396E (pt) | 2013-10-03 |
WO2005082379A1 (en) | 2005-09-09 |
DK2366396T3 (da) | 2013-09-08 |
DK1708721T3 (da) | 2013-09-08 |
JP4818127B2 (ja) | 2011-11-16 |
JP2007519718A (ja) | 2007-07-19 |
CA2554169A1 (en) | 2005-09-09 |
EP2366396A1 (en) | 2011-09-21 |
CA2554169C (en) | 2010-03-16 |
ES2426913T8 (es) | 2013-12-16 |
WO2005082379A8 (en) | 2006-01-19 |
CN1905887A (zh) | 2007-01-31 |
NZ548794A (en) | 2009-07-31 |
EP1708721A1 (en) | 2006-10-11 |
KR20060130630A (ko) | 2006-12-19 |
CY1115926T1 (el) | 2017-01-25 |
SI1708721T1 (sl) | 2013-10-30 |
ES2428843T8 (es) | 2013-12-26 |
IL177119A0 (en) | 2008-03-20 |
ES2426913T3 (es) | 2013-10-25 |
HK1162139A1 (en) | 2012-08-24 |
PT1708721E (pt) | 2013-10-02 |
IL177119A (en) | 2011-07-31 |
EP2366396B1 (en) | 2013-08-07 |
KR101143826B1 (ko) | 2012-05-11 |
CA2691611A1 (en) | 2005-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114928T1 (el) | Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης | |
EA200970469A1 (ru) | Антитела-агонисты рецептора trkb и их применение | |
EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
CY1117286T1 (el) | Μεσα και μεθοδοι για την αντιμετωπιση μυϊκων διαταραχων | |
EA201000211A1 (ru) | Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения | |
CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
EA201001253A1 (ru) | N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d | |
CY1119209T1 (el) | Αναστολεις κινασης τυροσινης bruton | |
EA200801369A1 (ru) | Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа | |
SV2006002143A (es) | Uso de un anticuerpo para el tratamiento del cancer resistente al platino | |
CY1109860T1 (el) | Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις | |
CY1112889T1 (el) | Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης | |
CR9304A (es) | Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos | |
EA200601761A1 (ru) | Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения | |
CL2004000860A1 (es) | Compuesto biciclico de pirazol o imidazol de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de un medicam | |
DE602006012725D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
ECSP10010322A (es) | Anticuerpos contra el virus de la influenza y métodos de uso de los mismos | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
BRPI0912411A8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro. | |
BRPI0314038B8 (pt) | anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica | |
ATE540673T1 (de) | Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis | |
EA200500520A1 (ru) | Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов | |
EA200700027A1 (ru) | Антагонисты рецептора глюкагона, их получение и терапевтическое применение | |
NO20072540L (no) | Anvendelse av A2A-adenosinreseptoragonist | |
DE602006015509D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung |